Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vicks Nears $1 Bil. In Sales Under “Focused” Growth Strategy – P&G

This article was originally published in The Tan Sheet

Executive Summary

The Vicks brand of over-the-counter cough, cold and flu products is "on its way" to becoming a $1 billion franchise, according to Procter & Gamble President and CEO A.G. Lafley

You may also be interested in...



Prilosec OTC Part Of “Engine Of Growth” P&G Expects From Health Care Sales

Procter & Gamble's Prilosec OTC (omeprazole) reached nearly 40 percent market share in the firm's latest quarter to lead the OTC heartburn medication segment

FTC Commissioner Proposes Making Endorsement Guides Into Rules, Seeking Stiffer Penalties

At least one FTC commissioner seems convinced that the agency’s Enforcement Guides are ripe for an update to address unscrupulous influencer marketing practices. Democrat Rohit Chopra proposes their codification into formal rules that would make violators liable for civil penalties and damages.

Ohio Study Shows Access To Naloxone Soars Without Rx Requirement

JAMA study finds that removing Rx requirement for naloxone in Ohio resulted in a 2,328% increase in orders of the drug dispensed since 2015. Michael Hufford, CEO of a company working on an OTC switch for a naloxone nasal spray, says the results show urgent need for a low-cost OTC product.

Topics

UsernamePublicRestriction

Register

PS100487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel